Mergers and acquisitions – Page 4
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
BusinessLilly and CureVac to collaborate on mRNA cancer vaccines
Deal could see CureVac net up to $1.8 billion in upfront and milestone payments
-
BusinessInvestor kills planned Huntsman–Clariant merger
Merger of equals abandoned after major Clariant investor said the deal would destroy stakeholder value
-
BusinessBASF to buy Bayer seeds and herbicides
€5.9bn sale will help satisfy competition regulators’ worries over Bayer–Monsanto merger
-
BusinessBASF to buy Solvay’s polyamide business
€1.6bn deal covers 2400 employees at sites in Europe, Asia and the Americas
-
BusinessTeva to sell off women’s health businesses for $1.4bn
Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts
-
BusinessTeva sells off contraceptive device in $1.1bn deal
CooperSurgical to acquire Paragard as Teva seeks to offload assets
-
BusinessHB Fuller targets growth with trio of deals
Adhesives manufacturer will buy one Brazilian and two US glue companies
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses
-
BusinessEU investigates Bayer’s Monsanto takeover plan
Commission raises concerns over reduced competition across pesticide and seed markets
-
BusinessMexichem to buy Netafim in $1.5bn deal
Takeover brings Netafim’s smart irrigation technology that could be applied across other markets
-
-
BusinessRoche offloads majority of rights to lebrikizumab
Deal with Dermira could be worth well over $1 billion
-
BusinessBristol-Myers Squibb bags immunotherapy unicorn
Deal will add to pharma giant’s cancer portfolio
-
BusinessGenesis Energy to buy alkali business from Tronox
Tronox to spend proceeds on Cristal purchase
-
BusinessMitsubishi Tanabe Pharma buys Neuroderm for $1.1 billion
Japanese pharmaceutical giant to acquire Israel’s Neuroderm in record breaking deal
-
BusinessEU to investigate Merck KGaA’s merger with Sigma–Aldrich
Commission says Merck failed to disclose a crucial research project
-
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs